In at least ten percent of asthma patients, there is an excessive symptom burden despite maximum controller therapy. A rational approach to treatment requires identifying one of three endotypes with distinct pathophysiology. Eosinophilic asthma, allergic asthma, and non-eosinophilic asthma can be differentiated by markers in blood and sputum. And targeted therapies have emerged, such as monoclonal antibodies to stages in the cytokine pathway that underlies eosinophil recruitment. It’s also important to consider the co-morbidities and risk factors that contribute to the disease, and to coordinate therapy in a multi-disciplinary way.
Guests: Professor Peter Gibson FRACP (Hunter Medical Research Institute, University of Newcastle), Professor Vanessa McDonald FRCNA (Hunter Medical Research Institute, University of Newcastle). Links to resources mentioned in the podcast are provided on the RACP website.
Create your
podcast in
minutes
It is Free